NEW YORK, NY / ACCESSWIRE / July 26, 2019 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
Heron Therapeutics, Inc. (HRTX)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/heron-therapeutics-inc-loss-submission-form?prid=2634&wire=1
Lead Plaintiff Deadline: August 5, 2019
Class Period: October 31, 2018 to April 30, 2019
Allegations against HRTX include that: (i) Heron had failed to include adequate Chemistry, Manufacturing, and Controls (“CMC”) and non-clinical information in its NDA for HTX-011; (ii) the foregoing increased the likelihood that the FDA would not approve Heron’s NDA for HTX-011; and (iii) as a result, Heron’s public statements were materially false and misleading at all relevant times.
EQT Corporation (EQT)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/eqt-corporation-loss-submission-form?prid=2634&wire=1
Lead Plaintiff Deadline: August 26, 2019
Class Period: June 19, 2017 to October 24, 2018
Allegations against EQT include that: (1) land acquired by the Rice Energy merger was not contiguous with the Company’s previously held acreage, which reduced the purported synergy benefits; (2) the purported longer lateral wells were not feasible because of intervening third-party parcels or prior drilling by EQT, Rice, or third parties; and (3) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Fred's, Inc. (FRED)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/freds-inc-loss-submission-form?prid=2634&wire=1
Lead Plaintiff Deadline: August 27, 2019
Class Period: December 20, 2016 to June 28, 2017
According to the filed complaint, defendants made numerous materially false and misleading statements concerning the level of regulatory risk faced by the Original Merger and the Revised Merger which would ultimately cause the termination of the Fred’s Asset Purchase Agreement. Specifically, Defendants made false and/or misleading statements: (i) downplaying or disputing contrary reports from journalists signaling regulatory turbulence in closing the merger; (ii) representing that inside knowledge of the FTC gave confidence that the deal would close.
To learn more contact Vincent Wong, Esq. either via email firstname.lastname@example.org or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
Vincent Wong, Esq.
39 East Broadway
New York, NY 10002
SOURCE: The Law Offices of Vincent Wong
View source version on accesswire.com: